New HPV vaccine aims to shield against extra cancer types
NCT ID NCT07224477
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests V540A, an experimental vaccine designed to protect against 9 HPV types already covered by Gardasil 9, plus additional unique types. About 525 healthy women aged 16-26 will receive either V540A or Gardasil 9 to compare safety and immune response. The goal is to see if V540A can offer broader protection against HPV-related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- V540A (experimental HPV vaccine)
- What this could lead to
- If successful, V540A could provide broader protection against HPV-related cancers by covering more virus types than current vaccines.
- What could go wrong
- This is an early phase 2 trial, so safety and immune response are still being tested. It may not prove more effective than existing vaccines, and side effects like injection-site pain are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test